市场调查报告书
商品编码
1451061
2024-2032 年按适应症(自体免疫疾病、肿瘤、代谢紊乱等)、类别(重组蛋白、单株抗体、纯化蛋白)和地区分類的生物製药市场报告Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2024-2032 |
2023年全球生物製药市场规模达到3,005亿美元。展望未来, IMARC Group预计到2032年市场规模将达到6,439亿美元,2024-2032年复合年增长率(CAGR)为8.6%。对个人化药物的需求不断增长、慢性病和生活方式相关疾病的盛行率不断上升,以及生物技术(包括基因工程和重组 DNA 技术)的快速进步,是推动市场成长的关键因素。
生物製药,也称为生物製剂,是一类从生物来源衍生出来的药物。它们是利用细菌、酵母或哺乳动物细胞等活生物体透过生物技术过程生产的。与化学合成的传统小分子药物不同,生物製药是大而复杂的分子,与体内的生物标靶表现出高度特异性的相互作用。与传统药物相比,它们具有多种优势。它们的作用往往具有高度特异性,通常针对特定受体或分子,从而提高疗效并减少副作用。此外,生物製药有可能治疗先前使用传统药物难以解决的疾病。
由于对个人化医疗的需求不断增长,该市场正在经历显着增长。此外,越来越多地利用生物製药来治疗癌症、糖尿病、牛皮癣和类风湿性关节炎,这是另一个主要的生长诱导因素。此外,大众对生物製药的有效性和可用性的认识不断增强,这是另一个主要的成长诱导因素。此外,对罕见疾病和孤儿药的日益关注正在推动市场的成长。这些罕见疾病的特征通常是患者群体较少,但医疗需求却未被满足。除此之外,世界各地的政府和监管机构还推出了激励措施并简化了监管流程,以鼓励开发这些疾病的疗法。此外,生物製药公司正在投资研发,开发针对罕见疾病的孤儿药,从而满足关键的医疗需求并创造市场扩张机会。
对个人化医疗的需求不断增长
个人化医疗导致生物製药市场转向标靶治疗和精准医疗方法。生物製药公司越来越注重开发针对特定基因突变、生物标记或与疾病相关的分子途径的疗法。此外,个人化医疗带来了药物基因组学的进步,药物基因组学是研究个体的基因组成如何影响其对药物的反应。了解影响药物代谢、功效和安全性的遗传变异可以识别可能面临不良反应风险的患者或更有可能对特定治疗产生良好反应的患者。这些知识使生物製药公司能够开发针对个别患者的针对性疗法和剂量方案,从而提高治疗效果并降低不良事件的风险。
慢性病和生活方式相关疾病的盛行率不断上升
慢性疾病,包括心血管疾病、糖尿病、癌症、呼吸系统疾病和自体免疫疾病,已成为全球主要的健康挑战。这些疾病往往具有复杂的潜在机制,需要有针对性和个人化的治疗方法。生物製药,如单株抗体、重组蛋白和基因疗法,提供精确的标靶和客製化的治疗选择。这些疗法可以针对与慢性疾病相关的特定分子途径、受体或细胞,从而提高疗效并减少副作用。此外,慢性病和生活方式相关疾病的负担日益增加,已将重点从症状缓解转向疾病改变和预防,这也推动了市场的成长。
生物技术的各种进步
生物技术大大加速了药物发现和开发进程。高通量筛选、组合化学和计算建模等先进技术可以在更短的时间内鑑定和测试大量候选药物。这提高了药物发现的效率和速度,使生物製药公司能够更快地将新疗法推向市场。此外,分析个别基因组成、识别疾病标记和了解分子途径的能力使得能够开发针对特定患者群体的标靶疗法。基因组学、下一代定序和基因编辑技术等生物技术工具彻底改变了对疾病机制的理解,并促进了针对特定遗传变异和分子标靶的疗法的开发,从而推动了市场的发展。
The global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. The escalating demand for personalized medicines, the growing prevalence of chronic and lifestyle-related diseases, and rapid advancements in biotechnology, including genetic engineering and recombinant DNA technology, are among the key factors driving the market growth.
Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from biological sources. They are produced using living organisms, such as bacteria, yeast, or mammalian cells, through biotechnological processes. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that exhibit highly specific interactions with biological targets in the body. They offer several advantages over traditional pharmaceuticals. They tend to be highly specific in their action, often targeting specific receptors or molecules, resulting in increased efficacy and reduced side effects. Additionally, biopharmaceuticals have the potential to treat diseases that were previously challenging to address using conventional drugs.
The market is experiencing significant growth due to the escalating demand for personalized medicine. In addition, the increasing utilization of biopharmaceuticals to treat cancer, diabetes, psoriasis, and rheumatoid arthritis represents another major growth-inducing factor. Besides, the growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals represents another major growth-inducing factor. Moreover, the rising focus on rare diseases and orphan drugs is driving the growth of the market. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Other than this, governments and regulatory agencies worldwide have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions. Moreover, biopharmaceutical companies are investing in R&D to develop orphan drugs, which target rare diseases, thereby addressing critical medical needs and creating opportunities for market expansion.
The escalating demand for personalized medicine
Personalized medicine has led to a shift toward targeted therapies and precision medicine approaches in the biopharmaceutical market. Biopharmaceutical companies are increasingly focusing on the development of therapies that target specific genetic mutations, biomarkers, or molecular pathways associated with diseases. Moreover, personalized medicine has led to advancements in pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to drugs. Understanding the genetic variations that impact drug metabolism, efficacy, and safety allows for the identification of patients who may be at risk of adverse reactions or those who are more likely to respond favorably to a specific treatment. This knowledge enables biopharmaceutical companies to develop targeted therapies and dosage regimens tailored to individual patients, enhancing treatment effectiveness and reducing the risk of adverse events.
The growing prevalence of chronic and lifestyle-related diseases
Chronic diseases, including cardiovascular disorders, diabetes, cancer, respiratory diseases, and autoimmune conditions, have become major global health challenges. These diseases often have complex underlying mechanisms, requiring targeted and personalized treatment approaches. Biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, offer precise targeting and tailored treatment options. These therapies can target specific molecular pathways, receptors, or cells associated with chronic diseases, resulting in enhanced efficacy and reduced side effects. Moreover, the increasing burden of chronic and lifestyle-related diseases has shifted the focus from symptomatic relief to disease modification and prevention, which is also propelling the market growth.
Various advancements in biotechnology
Biotechnology has greatly accelerated the drug discovery and development process. Advanced techniques, such as high-throughput screening, combinatorial chemistry, and computational modeling, enable the identification and testing of a large number of drug candidates in a shorter time frame. This has led to an increase in the efficiency and speed of drug discovery, allowing biopharmaceutical companies to bring new therapies to market more rapidly. Besides, the ability to analyze an individual's genetic makeup, identify disease markers, and understand molecular pathways has enabled the development of targeted therapies tailored to specific patient populations. Biotechnology tools, such as genomics, next-generation sequencing, and gene editing techniques, have revolutionized the understanding of disease mechanisms and enabled the development of therapies that address specific genetic variations and molecular targets, thus propelling the market.
IMARC Group provides an analysis of the key trends in each segment of the global biopharmaceutical market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and class.
Autoimmune Diseases
Oncology
Metabolic Disorders
Others
Autoimmune diseases represent the leading segment
The report has provided a detailed breakup and analysis of the market based on the indication. This includes autoimmune diseases, oncology, metabolic disorders, and others. According to the report, autoimmune diseases represented the largest segment.
Autoimmune diseases are often chronic and complex conditions that require long-term management and treatment. These diseases can affect multiple organs and systems in the body, leading to a wide range of symptoms and complications. Biopharmaceutical therapies have shown promising results in managing and controlling autoimmune diseases, providing relief from symptoms, slowing disease progression, and improving quality of life for patients. Therapies, including monoclonal antibodies and other biologics, have emerged as a vital treatment option for autoimmune diseases. They target specific molecules, cells, or pathways involved in the autoimmune response, providing more precise and effective therapeutic interventions.
Recombinant Proteins
Monoclonal Antibodies
Purified Proteins
Monoclonal antibodies exhibit a clear dominance in the market
A detailed breakup and analysis of the market based on the class has also been provided in the report. This includes recombinant proteins, monoclonal antibodies, and purified proteins. According to the report, monoclonal antibodies accounted for the largest market share.
Monoclonal antibodies are highly specific in targeting disease-specific antigens or cells. They are designed to bind to a specific target with precision, minimizing off-target effects and reducing the risk of adverse reactions. This specificity contributes to their efficacy in treating various diseases, including autoimmune disorders, cancer, inflammatory conditions, and infectious diseases. They also have a wide range of therapeutic applications across different disease areas. They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.
North America
United States
Canada
Latin America
Mexico
Brazil
Argentina
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Turkey
Asia Pacific
Japan
China
Australia
South Korea
India
Indonesia
North America accounts for the majority of market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Latin America (Mexico, Brazil, and Argentina); Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey); and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia). According to the report, North America was the largest market for biopharmaceuticals.
North America, particularly the United States, boasts a highly developed healthcare infrastructure, including robust research and development capabilities, advanced clinical facilities, and a strong regulatory framework. The region is home to renowned academic institutions, pharmaceutical companies, and research organizations that drive innovation in the biopharmaceutical industry. The presence of these institutions and infrastructure facilitates the development, manufacturing, and commercialization of biopharmaceutical products. The region has a well-established ecosystem that supports biopharmaceutical innovation, including government funding initiatives, research grants, venture capital investments, and collaborations between academia, industry, and research institutes.
The competitive landscape of the biopharmaceutical market is highly dynamic and competitive, with numerous global and regional players vying for market share. Nowadays, leading biopharmaceutical companies are heavily investing in R&D to discover and develop innovative therapies. They are conducting preclinical and clinical trials, and advance promising candidates through the regulatory approval process. These investments aim to expand their product pipelines, address unmet medical needs, and stay ahead of competitors in terms of therapeutic advancements. They are also forming strategic partnerships and collaborations with academic institutions, research organizations, and other industry players. These alliances enable them to access new technologies, scientific expertise, and complementary resources.
AbbVie Inc.
Amgen Inc
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Johnson & Johnson
Merck & Co. Inc.
Novo Nordisk A/S
Pfizer Inc.
Sanofi S.A
Pfizer and BioNTech developed and distributed their mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The vaccine received emergency use authorizations and has been widely deployed globally, playing a crucial role in combating the COVID-19 pandemic.
Amgen Inc. recently received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.
AbbVie Inc. has made significant advancements in immunology, particularly with its flagship product, Humira (adalimumab). Humira is one of the world's best-selling biologic drugs used to treat autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.